Pharmacokinetic studies with the antifolate C'-desamino-C2-methyl-7H-proargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscopy

D.R. Newell1, R.J. Maxwell2, G.M.F. Bisset1, D.I. Jodrell1 & J.R. Griffiths2

1Drug Development Section, Institute of Cancer Research, Sutton, Surrey SM2 5NG; and 2CRC Biomedical NMR Group, St George's Hospital Medical School, Tooting, London SW17 0RE, UK.

Summary In vivo 19F-NMR spectroscopy has been used to study the pharmacokinetics of the experimental antifolate drug CB3988 (C'-desamino-C2-methyl-7H-proargyl-2'-trifluoromethyl-5,8-dideazafolic acid) in mice and rats. These obtained results have been compared with those obtained by HPLC analysis. In mice, CB3988 was present at appreciable concentrations (about 20–30 mg ml-1) in both bile and urine which is consistent with the signal from the upper and lower abdomen being derived from the gall bladder and urinary bladder, respectively. In rats it was also indicated that CB3988 was cleared in both the upper and lower abdomen. NMR signal from the upper abdomen reached maximum intensity 10–40 min after administration, declining thereafter with a half life of 28 min. CB3988 was also detected in the lower abdomen reached maximum intensity 60–90 min after injection. 1H NMR spectra demonstrated that CB3988 was detectable both in the urine and abdominal fluid in rats. CB3988 is present in both the urine and abdominal fluid in rats. CB3988 is present in both the urine and abdominal fluid in rats.

In the present study the experimental antifolate C'-desamino-C2-methyl-7H-proargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988, Figure 1a) has been studied. CB3988 is the 2'-trifluoromethyl derivative of C'-desamino-C2-methyl-7H-proargyl-5,8-dideazafolic acid (ICI 198583, Figure 1b) which is itself an analogue of N7-propargyl-5,8-dideazafolic acid (CB3717, Figure 1c). Although CB3717 displayed clinical activity it was withdrawn from use because of a number of side effects which included renal and hepatic toxicities (Calvert et al., 1986). In experimental systems ICI 198583 is devoid of acute liver and kidney toxicity (Newell et al., 1988) and is, surprisingly, markedly more potent than CB3717 in cytotoxicity studies (Hughes et al., 1988; Jackman et al., 1988). The lack of toxicity seen with ICI 198583 is probably a reflection of its greatly enhanced aqueous solubility compared to CB3717 which is due to the lack of the 2-NH2 group in ICI 198583. In the case of CB3717, the presence of two hydrogen bond donors (N' and 2-NH3) and two hydrogen bond acceptors (O and N') allows strong intermolecular interactions and hence poor solubility. These interactions are reduced in the case of ICI 198583 which has a 2-methyl group instead of the 2-amino.

Stevens et al. (1984) were the first authors to demonstrate the utility of 19F-NMR as a method of non-invasively investigating the pharmacokinetics of a drug in vivo. These authors were able to measure drug in both the liver and tumours of mice following the administration of 5-fluourouracil (5FU) and were also able to detect metabolites of 5FU in both tissues. These studies have subsequently been extended to clinical investigations with 5FU (Wolf et al., 1987) and more recently with other fluorinated drugs, most notably the inhalational anesthetics (Wyrwich et al., 1987; Selinsky et al., 1988a, b). In the present study the experimental antifolate C'-desamino-C2-methyl-7H-proargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988, Figure 1a) has been studied. CB3988 is the 2'-trifluoromethyl derivative of C'-desamino-C2-methyl-7H-proargyl-5,8-dideazafolic acid (ICI 198583, Figure 1b) which is itself an analogue of N7-propargyl-5,8-dideazafolic acid (CB3717, Figure 1c). Although CB3717 displayed clinical activity it was withdrawn from use because of a number of side effects which included renal and hepatic toxicities (Calvert et al., 1986). In experimental systems ICI 198583 is devoid of acute liver and kidney toxicity (Newell et al., 1988) and is, surprisingly, markedly more potent than CB3717 in cytotoxicity studies (Hughes et al., 1988; Jackman et al., 1988). The lack of toxicity seen with ICI 198583 is probably a reflection of its greatly enhanced aqueous solubility compared to CB3717 which is due to the lack of the 2-NH2 group in ICI 198583. In the case of CB3717, the presence of two hydrogen bond donors (N' and 2-NH3) and two hydrogen bond acceptors (O and N') allows strong intermolecular interactions and hence poor solubility. These interactions are reduced in the case of ICI 198583 which has a 2-methyl group instead of the 2-amino.

In the present study the experimental antifolate C'-desamino-C2-methyl-7H-proargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988, Figure 1a) has been studied. CB3988 is the 2'-trifluoromethyl derivative of C'-desamino-C2-methyl-7H-proargyl-5,8-dideazafolic acid (ICI 198583, Figure 1b) which is itself an analogue of N7-propargyl-5,8-dideazafolic acid (CB3717, Figure 1c). Although CB3717 displayed clinical activity it was withdrawn from use because of a number of side effects which included renal and hepatic toxicities (Calvert et al., 1986). In experimental systems ICI 198583 is devoid of acute liver and kidney toxicity (Newell et al., 1988) and is, surprisingly, markedly more potent than CB3717 in cytotoxicity studies (Hughes et al., 1988; Jackman et al., 1988). The lack of toxicity seen with ICI 198583 is probably a reflection of its greatly enhanced aqueous solubility compared to CB3717 which is due to the lack of the 2-NH2 group in ICI 198583. In the case of CB3717, the presence of two hydrogen bond donors (N' and 2-NH3) and two hydrogen bond acceptors (O and N') allows strong intermolecular interactions and hence poor solubility. These interactions are reduced in the case of ICI 198583 which has a 2-methyl group instead of the 2-amino.

With CB3717 there is a clear relationship between the pharmacokinetics of the drug and its toxicities. Thus in both mice and patients the drug is nephrotoxic and this is associated with its accumulation and retention in the kidney (Alison et al., 1985; Newell et al., 1986). In mice the drug is

It is now accepted that pharmacokinetics are an important determinant of both the activity and toxicity of anticancer drugs (Newell, 1989). This acceptance has led to the inclusion of pharmacokinetic studies in both the preclinical and early clinical evaluation of the majority of novel antitumour agents with two broad aims in mind. Firstly, the studies may be of direct clinical relevance in determining dose escalation during phase I studies (Collins et al., 1986; EORTC PAM Group, 1987) and secondly the information gained may be of value in interpreting both the activity and toxicity of the compound. This latter information can in turn be used to develop either new drugs or drug schedules which maximise the therapeutic potential of the agent.

In order to conduct pharmacokinetic studies it is necessary to have a method which can accurately and selectively measure levels of the drug and its metabolites in biological fluids and tissues. Ideally the method should allow studies on drug levels in tumour deposits and in sensitive normal tissues since these are more likely to correlate with activity and toxicity than are levels in plasma or urine. In the preclinical setting such measurements are usually performed using radiochemicals and either autoradiographic or quantitative tissue distribution studies (Siddik & Newell, 1988). However, in patients ethical and clinical considerations restrict the use of radioactive tracers and routine sampling of tumour or normal tissue is not practicable. Hence, in the majority of studies in patients, pharmacokinetic data are derived from the study of readily accessible body fluids, i.e. blood, urine and occasionally bile and CSF. Using physiological pharmacokinetic modelling it is possible to extract some tissue distribution information from such data although there is always considerable uncertainty attached to the results because of interpatient variation. Thus there is no substitute for direct drug analysis in the tissue of interest.

Correspondence: D.R. Newell, The University of Newcastle upon Tyne, Division of Oncology, Cancer Research Unit, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. Received 19 October 1989; and in revised form 10 July 1990.
hepatotoxic and this is also associated with CB3717 retention in the liver (Newell et al., 1986). In contrast, in mice, the non-toxic ICI 198583 is not retained in either the liver or the kidney (Newell et al., 1988).

The aim of the present study was to confirm the rapid clearance of ICI 198583 from the liver and kidney by using $^{19}$F-NMR spectroscopy and in so doing to evaluate the potential NMR as a non-invasive method for pharmacokinetic monitoring. To achieve this aim the 2′ trifluoromethyl derivative of ICI 198583 was synthesised and the clearance of the drug from the liver and the appearance of the drug in the urinary bladder determined in mice. In addition, a study was performed in both normal and bile duct cannulated rats to determine the contribution of enterohepatic circulation to the NMR signal derived from the upper abdomen of the rat. The results obtained in mice by NMR were compared to those obtained using high performance liquid chromatography (HPLC) and in the rat the results obtained with CB3988 were compared to those gained with ICI 198583 to exclude the possibility that the present of the 2′ trifluoromethyl was markedly influencing the pharmacokinetics of the drug. Certain aspects of this study have been reported previously in abstract form (Newell et al., 1988).

Materials and methods

Materials

Male C57BL × DBA2 F1 hybrid mice (25–30 g) and female Wistar rats (180–220 g) were supplied by the National Institute of Medical Research, Mill Hill, London. CB3988 was synthesised as described below and ICI 198583 was a generous gift from ICI Pharmaceuticals plc, Macclesfield, Cheshire. All other chemicals were of analytical grade where available and obtained from standard suppliers.

Synthesis of CB3988

The synthesis of CB3988 (Hughes, 1986; Marsham et al., 1990) was achieved as outlined in Figure 2. Diazo-tization of the nitro aniline (1) and subsequent displacement of the diazo group by cyanide anion give the nitrile (2). Hydrolysis of the nitrile to carboxylate (4) was problematic, but was eventually achieved in two steps via the amide (3). Diethyl glutamate was condensed efficiently with the carboxylate acid chloride to give the nitro glutamate (5), which was then hydrogenated and the resulting amine (6) propargylated to give (7). Propargylamine (7) was coupled to bromomethyl quinazoline (8) and the coupled diester (9) hydrolysed to give CB3988 in good overall yield.

In vivo $^{19}$F-NMR spectroscopy

Studies in mice $^{19}$F-NMR spectra were obtained using an Oxford Research Systems TMR-32 spectrometer with a 1.9T horizontal bore magnet. Mice were anaesthetised with 60 mg kg$^{-1}$ pentobarbitone intraperitoneally (i.p.) and when anaesthetised the urethra was ligated externally to prevent urination. The tail of the animal was warmed (42°C) and CB3988 given intravenously (i.v.) into a tail vein at 500 mg kg$^{-1}$ (50 mg ml$^{-1}$ in 0.15 M NaHCO$_3$, final pH adjusted to 9–9.5 with NaOH). Mice were then placed on a flask pumped with warm water so as to maintain the body temperature of the mouse at 36–38°C. The mouse and flask were then placed in the bore of the magnet and a 14 mm diameter two-turn

Figure 1 The structures of CB3988 (a), ICI 198583 (b), and CB3717 (c).
surface coil placed over the upper or lower abdomen to detect signal originating in the liver and urinary bladder, respectively. NMR data were obtained using a 12 μs pulse and a 1 s pulse repetition interval. A pulse width of 12 μs was found to give maximum signal intensity from a fluorescence-containing spherical phantom of 1 cm diameter, placed immediately under the surface coil. The 90° pulse at the coil centre was 5 μs. Data were collected in 4–8 min blocks for up to 2 h. Data processing involved exponential multiplication of the free induction decay equivalent to 40 Hz line broadening. Additional anaesthetic was given as required (15 mg kg⁻¹ i.p.) without moving the animal.

Studies in rats Rats were anaesthetised with 60 mg kg⁻¹ pentobarbitone i.p. and the trachea, left carotid artery and left femoral vein cannulated with polyethylene tubing. The pulse rate of the rat was recorded on an oscilloscope, the femoral cannulae was monitored throughout the experiment with 10 i.u. ml⁻¹ heparin in saline. The urethra was ligated externally to prevent urination during the experiment. In experiments where the effect of interrupting the enterohepatic cycle of CB3998 were conducted the common bile duct was also cannulated. Once surgery was complete the rat was placed on a flask pumped with warm water and the body temperature allowed to equilibrate at 36–38°C. The rat and flask were then placed in the bore of the magnet and pretreatment samples of blood collected from the carotid artery and, when cannulated, from the bile duct. NMR spectra were recorded by placing the surface coil over the upper abdomen of the rat and, after a pretreatment spectrum was recorded, CB3998 was given at 100 mg kg⁻¹ as an i.v. bolus dose via the femoral vein (50 mg ml⁻¹ in 0.15 M NaHCO₃, pH 9.5 with NaOH). Spectra were recorded as described for mice with the exception that a pulse width of 14 μs was employed. Data were collected for up to 60 min with additional anaesthetic being given i.v. as required at 15 ml kg⁻¹. During the course of the experiment a cumulative bile sample was collected and blood samples (200 μl) taken 5, 10, 15, 20, 25, 30, 45 and 60 min after CB3998 administration. Plasma was prepared by centrifugation. At the end of the experiment the rats were killed with an overdose of anaesthetic and the contents of the bladder removed. All samples were weighed and stored at −20°C prior to analysis by HPLC. In both mice and rats the doses of CB3998 used produced no acute toxicity.

Determination of CB3998 concentrations by HPLC Mouse samples In a separate series of experiments (Maxwell et al., 1990) CB3998 was administered to pentobarbitone-anaesthetized rats described above. After administration the mice were killed and the liver, small intestine, large intestine, kidneys, lung, heart, spleen and stomach removed. The gall bladder was separated from the liver and the contents of the urinary bladder were removed. All samples were weighed and then stored at −20°C until analysed. For HPLC analysis, samples were homogenised in a teflon/glass homogeniser in 9 volumes of 0.1 M Tris-HCl pH 10 buffer and urine and bile diluted in the same buffer to give CB3998 concentrations in the range 0.1–50 mg ml⁻¹. Aliquots of 0.5 ml of the diluted urine, bile and tissue homogenates were treated with 1 ml methanol and any resultant precipitate removed by centrifugation for 15 min at 1,500 g at 4°C. Aliquots (25 μl) of the resultant supernatants were analysed using a Waters Associates chromatograph (Millipore, Harrow, UK) fitted with a 5 μm 15 × 0.46 cm Spherisorb ODS columns (Pharmacia) and a 5 × 2.1 cm CO2:Pell ODS precolumn (Whatman, Clifton, NJ, USA). The column was eluted isocratically with 40:60 methanol:0.18 M acetic acid (v:v) at a flow rate of 1.5 ml min⁻¹. CB3998 was detected by UV absorbance at 280 nm and 313 nm and concentrations were calculated by external standardisation by comparison of peak areas to those of CB3998 standards in the same buffer. Analyses were conducted in triplicate on the lower abdomen of mice 40, 80 and 120 min after the i.v. administration of 500 mg kg⁻¹ CB3998. These data show that the NMR signal for 19F was readily detectable at these time points; however, the signal was near the limit of detection at 120 min. No clear evidence of the presence of additional peaks in the NMR spectrum was seen at any time point and hence metabolism of CB3998 at a site close enough to the 2' position to substantially alter the chemical shift of the trifluoromethyl signal is not indicated. Figure 4 displays the time course for the appearance and disappearance of the signal in the upper abdomen of mice and shows that the signal tended to increase over the first 10–40 min, decaying thereafter. The half-lives for the decline in peak intensity during the exponential phase. Half-lives were calculated by non-linear least squares regression analysis (Jennrich & Sampson, 1968) using a weighting function of 1/(y + y²).

Plasma levels of CB3998 and ICI 198583 in rats A biexponential equation was fitted to plasma CB3998 and ICI 198583 levels following their administration to rats. As above, non-linear least squares regression analysis employing a weighting function of 1/(y + y²) was used. From the fitted equation the alpha and beta phase half-lives, clearance and volume of distribution at steady state were calculated using standard equations (Houston, 1985).

Results

19F-NMR spectroscopy of CB3998 in mice

Figure 3 shows examples of the spectra obtained from the upper abdomen of mice 40, 80 and 120 min after the i.v. administration of 500 mg kg⁻¹ CB3998. These data show that the NMR signal was readily detectable at these time points; however, the signal was near the limit of detection at 120 min. No clear evidence of the presence of additional peaks in the NMR spectrum was seen at any time point and hence metabolism of CB3998 at a site close enough to the 2' position to substantially alter the chemical shift of the trifluoromethyl signal is not indicated. Figure 4 displays the time course for the appearance and disappearance of the signal in the upper abdomen of mice and shows that the signal tended to increase over the first 10–40 min, decaying thereafter. The half-lives for the decline in peak intensity during the exponential phase. Half-lives were calculated by non-linear least squares regression analysis (Jennrich & Sampson, 1968) using a weighting function of 1/(y + y²).
**F-NMR spectroscopy of a quinazoline antifolate**

CB3988 concentrations in mouse tissues 30 and 60 min after the administration of 500 mg kg\(^{-1}\) i.v.

| Tissue       | Conc. | %Dose | Conc. | %Dose  |
|--------------|-------|-------|-------|--------|
| Liver        | 0.13±0.1 | 17±2 | 0.23±0.6 | 15±2   |
| Kidney       | 0.8±0.8    | 2.3±2.4 | 0.6±0.7   | 1.8±2.2 |
| Heart        | 0.10±0.04  | 0.13±0.05 | 0.05±0.03 | 0.02±0.02 |
| Spleen       | 0.05±0.01  | 0.03±0.01 | 0.03±0.03 | 0.02±0.02 |
| Stomach      | 0.10±0.08  | 0.30±0.25 | 0.06±0.02 | 0.23±0.09 |
| Lung         | 0.18±0.09  | 0.29±0.18 | 0.10±0.09 | 0.13±0.12 |
| Intestine    | 0.07±0.02  | 0.42±0.23 | ND      | ND     |
| Urine        | 25±12     | 18±1   | 26±4   | 31±4   |
| Bile         | 26±15     | 1.3±1.2 | 23±4   | 1.3±0.6 |
| Small intestine | 1.3±0.9 | 13±8   | 2.6±0.4 | 28±8   |

Concentrations are mg CB3988 per ml urine or bile and per g wet weight for the tissues analysed. %Dose is the % of the dose administered present in the total sample. ND, <0.02 mg g\(^{-1}\) wet weight. Values are the mean ± standard deviation of data from 3–4 mice.

**F-NMR spectroscopy of CB3988 in rats**

The time course for the appearance and decline of NMR signal from the upper abdomen of rats following the administration of 100 mg kg\(^{-1}\) CB3988 is shown in Figure 6. Data for rats with intact and cannulated bile ducts are given and, as in the case of mice, all spectra contained only the peak associated with CB3988, no metabolites being detected. In both cannulated and bile duct-intact rats, NMR signal was detected within 2 min of the bolus dose of CB3988 with signal intensity reaching a maximum value by 10 min. Thereafter the signal declined rapidly, particularly in bile duct cannulated rats where the limit of detection was reached by 15–20 min and signal was not detected again during the remainder of the experiment (60 min). The half-lives for the decline in the NMR in the three bile duct cannulated rats were 6.5±0.8, 6.9±0.8 and 5.6±2.9 min, overall mean 6.5±0.8 min. In the rats with intact bile ducts the NMR signal did not decline as rapidly as in the cannulated rats and did not drop below the limit of detection during the experiment (0–60 min). Indeed, in two of the rats, from 30 min onwards the NMR signal had stabilised. These data suggest that the signal detected in rats with intact bile ducts is due in
Figure 7 Plasma concentrations of CB3988 (O, Δ) and ICI 198583 (□) in rats following 100 mg kg⁻¹ i.v. Data for CB3988 are from rats with intact bile ducts (□) and those with cannulated bile ducts (Δ). Points are the mean of estimations in three rats for each treatment and bars the standard deviations of the means.

Table II Effect of bile duct cannulation and the 2' trifluoromethyl group on the pharmacokinetics of CB3988 in the rat (100 mg kg⁻¹ i.v.)

| Compound | Bile duct cannula | CB3988 | CB3988 | ICI 198583 |
|----------|-------------------|--------|--------|------------|
|          |                   |        |        |            |
| t₀α | Alpha (min) | 4.1 ± 1.0 | 3.3 ± 0.8 | 6.1 ± 0.9 |
| t₁,2 | Beta (min)    | 22.4 ± 7.8 | 27.2 ± 12 | 30 ± 8 |
| Vₚ | (ml kg⁻¹)     | 105 ± 24 | 104 ± 13 | 128 ± 15 |
| Vₘ (ml kg⁻¹) | 168 ± 25 | 217 ± 61 | 229 ± 83 |
| Clearance (ml min⁻¹kg⁻¹) | 14.2 ± 3.1 | 15.4 ± 3.0 | 10.6 ± 1.6 |
| Excretion (% dose, 0–60 min) | | | |
| Biliary | | 77 ± 7 | 75 ± 8 |
| Urinary | | 7.6 ± 0.7 | 9.7 ± 1.0 | ND |

Values are the mean ± s.d. from three rats for each treatment. ND, the 0–60 min urinary excretion for ICI 198583 was not determined, but the 0–240 min cumulative urinary excretion was 17.3 ± 6.0% of the dose. Vₚ, apparent volume of the central compartment. Vₘ, apparent volume of distribution at steady state. Clearance, total plasma clearance.

Discussion

The aim of the present study was to evaluate the utility of non-invasive ¹⁹F-NMR spectroscopy as a method of studying the pharmacokinetics of the antifolate CB3988 in mice and rats. This study is important both with regard to this particular class of compounds and because there is a general need to study non-invasive methods of pharmacokinetic monitoring in cancer chemotherapy. In both mice and rats NMR signal could be readily detected in the upper abdomen of the animal shortly after drug administration. Comparison of the NMR data with those of a conventional quantitative tissue distribution study performed using HPLC analysis demonstrated that the signal in the upper abdomen of mice was probably derived from the gall bladder. Associated studies using whole body ¹⁹F-NMR imaging in mice following the administration of CB3988 confirm that the signal from the upper abdomen is derived from a discreet volume whose position is anatomically consistent with that of the gall bladder (Maxwell et al., 1990). The other area examined in mice was the lower abdomen where signal was also readily detected. Again on the basis of HPLC analyses (Table II) and ¹⁹F-NMR imaging (Maxwell et al., 1990) the source of the signal would appear to be primarily the urinary bladder. The time course of the appearance of the drug in the bladder indicates that the urinary excretion of the drug occurs rapidly and is essentially complete within 1 h (Figure 5). This is in marked contrast to the nephrotoxin CB3717 where there is a delayed urinary excretion and drug still present in the kidney weeks after administration (Newell et al., 1986). Thus NMR does appear to be capable of monitoring urinary excretion with this class of compound. In the light of clinical experience with CB3717 (Calvert et al., 1986; Alisson et al., 1985) this information would be useful in the early clinical evaluation of CB3717 analogues.

In addition of urinary excretion, faecal elimination constitutes the major route of excretion for CB3717 (Newell et al., 1986) and its analogues (Newell et al., 1988). Faecal elimination is preceded by biliary excretion, and the majority of the dose present in the bile within 1 h in the case of both ICI 198583 and CB3988 (Table II). This is also the case for CB3717 itself at non-hepatotoxic doses (Newell & Siddik, unpublished results). Since biliary excretion is the major route of elimination, and the NMR signal from the upper abdomen of mice derives from the bile in the gall bladder, a relationship between the rate of decline in the plasma levels of CB3988 and the NMR signal might be anticipated. Although the plasma levels of CB3988 in mice were not determined as part of the present study, previous results with other C²-desamino quinazolines indicate that the plasma half-life is approximately 20 min (Newell et al., 1988). This value is consistent with that of 28 ± 6 min for the decline in the NMR signal reported herein. Thus for drugs which undergo extensive biliary elimination NMR studies of drug clearance from the liver may offer an indirect measure of plasma half-life. More generally, in those cases where drugs can be detected in organs of direct therapeutic or toxicological interest the results of NMR experiments may be more relevant than plasma analyses. For example, the relationship between drug levels in tumour tissue and activity should be better than that between plasma levels and activity.

Experiments were performed in rats to further investigate the relationship between CB3988 plasma half-life and the decline in NMR signal since it was technically possible to take blood samples, collect bile and perform spectroscopic experiments on the same animal. The experiments in bile duct cannulated rats, where enterohepatic circulation cannot occur, indicated that the alpha phase half-life for the clearance of CB3988 from plasma was 3.6 ± 0.3 min while the NMR signal from the upper abdomen decreased with a half-life of 6.5 ± 0.8 min. The similarity of these results again encourages the view that the signal from the liver can be used as an indirect measure of the plasma half-life of a drug, provided that the liver is the major organ for the clearance of the compound. When experiments were repeated in rats with an intact bile duct a more complex profile was obtained for the time course of NMR signal intensity from the upper abdomen (Figure 6). The difference between these results and those obtained in bile duct cannulated rats strongly suggests an element of enterohepatic circulation in the disposition of the drug. Enterohepatic circulation has been observed in rats with CB3717 (Newell & Siddik, unpublished results) and
methotrexate (Griffin & Said, 1987), and hence is not unexpected.

The rapid decline in the NMR signal from the liver of both mice and rats following CB3988 administration is again in contrast to the data obtained in mice (Newell et al., 1986) and rats (Newell & Siddik, unpublished results) with CB3717. In both species reduced clearance of the drug from the liver was associated with hepatotoxicity. With C²-desamino analogues of CB3717 both retention of drug in the liver and hepatotoxicity are absent (Newell et al., 1988). However, these results were obtained using invasive techniques. The demonstration in the present study that it is possible to show rapid hepatic clearance non-invasively by NMR is again an encouraging result which would also be of value in the early clinical evaluation of CB3717 analogues.

The final point investigated in this study concerned the impart of the inclusion of the 2'-trifluoromethyl group on the pharmacokinetics of the antifolate molecule. In this respect the only significant effect of the 2'-trifluoromethyl group was to reduce the alpha phase half-life value with the result that plasma levels of CB3988 were lower than those of ICI 198583 (Figure 7). No other major qualitative or quantitative alterations in the distribution of the molecule, its clearance or its routes of elimination were observed.

However, it should be noted that associated biochemical studies have shown that the presence of the 2'-trifluoromethyl group reduces both the inhibitory activity of the compound towards the target enzyme, thymidylate synthase (7-fold), and the cytotoxicity of the agent (14-fold) in comparison to ICI 198583 (A.L. Jackman, unpublished results). Thus the potential problems of including the trifluoromethyl group as a 'label' in candidate drugs should not be underestimated and the use of a single fluorine atom may be more appropriate, but the resultant loss in sensitivity might compromise the utility of the methodology.

With regard to the general application of 19F-NMR in pharmacokinetic studies a number of points need to be considered. The major limitation of NMR is that the technique has only limited sensitivity. Thus in the present study signal detected in the upper and lower abdomen of mice was ascribed to drug present in the bile and urine at concentrations of 20–30 mg ml⁻¹ (40–60 mM). The dynamic range in these studies was approximately 10-fold and hence that limit of detection would be in the region of 4 mM. This figure could be reduced by the use of longer acquisition periods; however, in so doing time resolution would be lost which may be critical in the case of drugs with short half-lives. In contrast, conventional methods involving radiochemical and/or chromatographic analyses can provide information on drug levels in the low nM region. Thus, in the absence of marked improvements in sensitivity, in vivo 19F-NMR will only find application in those cases where relatively large doses of drug can be administered. This was possible in the case of CB3988 as C²-desamino quinazoline antifolates can be administered to mice at 500 mg kg⁻¹ without producing any acute toxicity (Newell et al., 1988). Since a number of antitumour agents are relatively impotent compounds, with clinical doses in the 100 mg to 1g range, cancer chemotherapy improvements in sensitivity, in vivo 19F-NMR will only find application in those cases where relatively large doses of drug can be administered. This was possible in the case of CB3988 as C²-desamino quinazoline antifolates can be administered to mice at 500 mg kg⁻¹ without producing any acute toxicity (Newell et al., 1988).

Despite the limitations of sensitivity with regard to in vivo spectroscopy, it is already clear that ex vivo analytical 19F-NMR does have considerable potential as a method to study drug and metabolite levels using biological fluids and isolated tissues. A number of studies have already shown the utility of the method in the case of the fluoropyrimidine drugs (Malet-Martino et al., 1984, 1986; Keniry et al., 1986; Vialaneix et al., 1987; Hull et al., 1988). The use of 'fluorine labels' in other anticancer drugs is clearly warranted and recent work with nitroimidazoles is a further example of this (Maxwell et al., 1989). The studies with the fluoropyrimidines serve to highlight the major strength of NMR over radiochemical studies, namely, that the technique provides separate information on drug metabolites and the parent compound and not just on total drug derived material. This aspect of 19F-NMR was not apparent from the study reported in the present paper because quinazoline antifolates do not undergo extensive metabolism. Thus in the case of CB3717, the only extracellular metabolite which has been detected is the desglutamate compound which was found in the faeces and was shown to be a product of bacterial metabolism in the gastrointestinal tract (Newell et al., 1986). Although polyglutamate metabolites of CB3717 have also been detected, both in vitro (Sikora et al., 1988) and in vivo (Manteufel-Cymborowska et al., 1986; Nair et al., 1986), these compounds are thought to be rapidly catabolised once outside the cell. Within the cell polyglutamates are probably highly protein bound and would not have the freedom of motion required for a molecule to be detected by NMR. This requirement for molecules to be free to move in order to be detected by NMR spectroscopy may place an additional limitation on the detection of drugs in biological tissues since the line widths of NMR signals depends upon the rotational freedom of the nuclei involved. Thus the binding of a small molecule to a protein can result in line broadening to such an extent that some or all of the nuclei become 'NMR invisible'. Preliminary studies with CB3988 indicated that when the drug was added at 2 mM to a 50% (v/v) mouse liver homogenate the peak height signal to noise ratio was reduced 4-fold relative to an aqueous solution of the drug at the same concentration. Further experiments are required to define the extent to which this phenomenon will limit the application of in vivo NMR.

In conclusion, this study has demonstrated the utility of in vivo 19F-NMR spectroscopy as a method for studying the pharmacokinetics of a quinazoline antifolate drug in mice and rats. The results obtained by NMR indicate that CB3988 is cleared rapidly by both biliary and urinary elimination. These data are consistent with the lack of liver and kidney toxicity found with the C²-desamino CB3717 analogues. Comparison of the NMR data with data obtained using conventional HPLC methodology indicates that the NMR signals detected in the upper and lower abdomen of mice are derived from the gall bladder and urinary bladder, respectively. Pharmacokinetic analyses in both mice and rats suggest that the rate of decline of the NMR signal derived from the upper abdomen may reflect the rate of drug clearance from the plasma and that in rats NMR can detect compound undergoing enterohepatic circulation. Comparison of the pharmacokinetics of CB3988 and ICI 198583 in rats indicated that the inclusion of the 2' trifluoromethyl group reduced the alpha phase half life, however, it did not markedly alter the rate or route of drug clearance. In view of the non-hazardous nature of in vivo NMR spectroscopy the studies reported here are directly applicable to clinical investigations with the potential to provide hitherto unobtainable information.

This work was supported by grants from the Cancer Research Campaign and Medical Research Council. The authors are grateful to Professor A.H. Calvert for his interest and to Dr T.R. Jones for his encouragement during the planning stages of this project.

References

ALISON, D.L., NEWELL, D.R., SESSA, C. & 4 others (1985). The clinical pharmacokinetics of the novel antifolate N⁵-propargyl-8,9-dideazafolic acid (CB3717). Cancer Chemother. Pharmacol., 14, 265.

CALVERT, A.H., ALISON, D.L., HARLAND, S.J. & 9 others (1986). A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N⁵-propargyl-8,9-dideazafolic acid. J. Clin. Oncol., 4, 1245.
COLLINS, J.M., ZAHARKO, D.S., DEDRICK, R.L. & 1 other (1986). Potential roles for flavonoids in phase I clinical studies. Cancer Treat. Rep., 70, 73.

EORTC PHARMACOKINETICS AND METABOLISM GROUP (1987). Pharmacokinetic studies of drug coadministration in phase I clinical studies. CONOR, 19, 54.

GRIFFIN, D. & SAID, H.M. (1987). The enterohepatic circulation of methotrexate in vivo: Inhibition by bile salt. Cancer Chemother. Pharmacol., 19, 40.

HOUSTON, J.B. (1985). Kinetics of drug metabolism and disposition: physiological determinants. In Drug Metabolism and Disposition: Considerations in Clinical Pharmacology, Wilkinson, G.R. & Rawlins, M.D. (eds), p. 63. TTP Press: Lancaster.

HUGHES, L.R. (1986). Preparation of N-[[3,4-dihydro-4-oxo-6-quinazolyl]methyl] amino] aryl amino acids as anti-tumour agents. GB Patent Appl. 86/7683.

HUGHES, L.R., MARSHAM, P.R., OLDFIELD, J. & 5 others (1988). Thymidylate synthase (TS) inhibition and cytostatic activity of a series of C5 substituted -5,8-dideazafolates. Proc. Am. Assoc. Cancer Res., 29, 286.

HULL, W.E., PORT, R.E., HERRMANN, R. & 2 others (1988). Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res., 48, 1680.

JACKMAN, A.L., TAYLOR, G.A., MORAN, R. & 6 others (1988). Biochemical properties of 2-desamino-2 substituted -5,8-dideazafolates that inhibit thymidylate synthase (TS). Proc. Am. Assoc. Cancer Res., 29, 287.

JENNIRICH, R.I. & SAMPSON, P.F. (1968). Application of a stepwise regression to non-linear least squares estimation. Technometrics, 10, 63.

KENRY, M., BENZ, C., SHAFFER, R.H. & 1 other (1986). Noninvasive spectroscopic studies in clinical and experimental tumour cells. Cancer Res., 46, 1754.

MALET-MARTINO, M.-C., MARTINO, R., LOPEZ, A. & 4 others (1984). New approach to metabolism of 5’deoxy-5’fluorouridine in humans with fluorine-19 NMR. Cancer Chemother. Pharmacol., 13, 3.

MALET-MARTINO, M.-C., FAURE, F., VIALANEIZ, J.-P. & 3 others (1986). Non-invasive fluorine-19 NMR study of fluoropyrimidine metabolism in cultures of human pancreatic and colon adenocarcinomas. Cancer Chemother. Pharmacol., 18, 5.

MANTEUFFEL-CYMBOROWSKA, M., SIKORA, E. & GRZELAKOWSKA-SZTABERT, B. (1986). Polyglutamylation of the antifolate anticancer drug N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Anticancer Res., 6, 807.

MARSHAM, P.R., JACKMAN, A.L., HUGHES, L.R. & 6 others (1990). Quinazoline antifolate thymidylate synthase inhibitors: benzoyl ring modifications in the C2-methyl series. J. Med. Chem. (in the press).

MAXWELL, R.J., WORKMAN, P. & GRIFFITHS, I.R. (1989). Demonstration of tumour-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int. J. Radiat. Oncol. Biol. Phys., 16, 925.

MAXWELL, R.J., FRENKIEL, T.A. NEWELL, D.R. & 2 others (1990). 19F-NMR imaging of drug distribution in vivo: the disposition of an antifolate anticancer drug in mice. Magn. Reson. Med. (in the press).

NAIR, M.G., METHA, A.P. & NAIR, I.G. (1986). The metabolism of N10-(propargyl)-5,8-dideazafolic acid (PDDF) in mice. Fedn. Proc., 45, 821.

NEWELL, D.R., ALISON, D.L., CALVERT, A.H. & 5 others (1986). Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat. Rep., 70, 971.

NEWELL, D.R., MAXWELL, R.J., GRIFFITHS, J.R. & 3 others (1988). Pharmacokinetic and toxicity studies with C2-desamino-C2-substituted analogues of N5-propargyl-5,8-dideazafolic acid (CB3717). Proc. Am. Assoc. Cancer Res., 29, 286.

NEWELL, D.R. (1989). Pharmacokinetic determinants of the activity and toxicity of antimetabolite agents. Cancer Surv., 8, 557.

SELINSKY, B.S., THOMPSON, M. & LONDON, R.E. (1987). Measurement of in vivo hepatic halothane metabolism using 19F-NMR spectroscopy. Biochem. Pharmacol., 36, 413.

SELINSKY, B.S., PERLMAN, M.E. & LONDON, R.E. (1988a). In vivo nuclear magnetic resonance studies of methoxyflurane metabolism I. Verification and quantitation of methoxydifluorooacetate. Mol. Pharmacol., 33, 559.

SELINSKY, B.S., PERLMAN, M.E. & LONDON, R.E. (1988b). In vivo nuclear magnetic resonance studies of hepatic methoxyflurane metabolism II. A re-evaluation of hepatic metabolic pathways. Mol. Pharmacol., 33, 567.

SIKORA, E., JACKMAN, A.L., NEWELL, D.R. & 1 other (1988). Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem. Pharmacol., 37, 4047.

SIDDIK, Z.H. & NEWELL, D.R. (1988). Radiochemicals in cancer research and clinical oncology. In Radiochemicals in Biomedical Research, Evans, E.A. & Oldham, K.G. (eds) p. 118. John Wiley and Sons: Chichester.

STEVENS, A.N., MORRIS, P.G., ILES, R.A. & 2 others (1984). 5-Fluorouracil metabolism monitored in vivo by 19F NMR. Br. J. Cancer, 50, 113.

VIALANEIZ, J.-P., MALET-MARTINO, M.C., HOFFMANN, J.S. & 2 others (1987). Direct detection of new fluorocytosine metabolites in human biofluids by 19F nuclear magnetic resonance. Drug Metab. Disp., 15, 718.

WOLF, W., ALBRIGHT, M.J., SILVER, M.S. & 3 others (1987). Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imag., 5, 165.

WYRWICZ, A.M., CONBOY, C.B., RYBACK, K.R. & 2 others (1987). In vivo 19F-NMR study of isoflurane elimination from brain. Biochim. Biophys. Acta, 927, 86.